All In Biotech

Drug Trial Radar · NCT05390905

A Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in Patients for Postoperative Pain Treatment

A Multi-Center, Randomized, Double-Blind, Placebo/Active-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HSK21542 Injection for Postoperative Pain Treatment

Last checked: Nov 20, 2026Latest source record: Apr 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 387 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

387

Actual

Start

Jun 8, 2022

Primary completion

Dec 16, 2022

Study completion Mar 28, 2023

Sponsor

Sponsor type
Industry
First posted
May 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, double-blind, placebo/active-controlled study. About 387 subjects undergoing elective abdominal operation under general anesthesia are planned to be enrolled and randomized into the HSK21542 group (129 subjects), tramadol group (129 subjects), and placebo group (129 subjects).

Conditions

  • Postoperative Analgesia

Interventions

  • HSK21542 InjectionDrug

    1μg/kg/dose

  • Tramadol hydrochlorideDrug

    50mg/dose

  • placeboDrug

    placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sum of Pain Intensity Differences (SPID) in the HSK21542 group and the placebo groupTime frame: From administration until 24 hours after administration
  2. Sum of Pain Intensity Differences (SPID) in tramadol group and the placebo groupTime frame: From administration until 24 hours after administration
  3. Sum of Pain Intensity Differences (SPID) in the HSK21542 group and the tramadol groupTime frame: From administration until 24 hours after administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Union Hospital, Tongji Medical College, Huazhong U

    Wuhan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.